<DOC>
	<DOCNO>NCT01479036</DOCNO>
	<brief_summary>This study design determine efficacy safety neoadjuvant docetaxel epirubicin ( DE ) without human recombinant endostatin ( endostar ) breast cancer patient . The hypothesis protocol combine angiogenesis inhibit therapy chemotherapy could benefit breast cancer patient .</brief_summary>
	<brief_title>Trial Neoadjuvant Endostar , Docetaxel Epirubicin Patients With Breast Cancer</brief_title>
	<detailed_description>This multicenter , prospective , randomize , control phase Ⅲ clinical trial . A total 800 patient core-biopsy confirm breast cancer , stage ⅡA ⅢC , treat neoadjuvant systemic therapy eligible entry study . Patients allocate randomly two group receive either 3 cycle neoadjuvant DE endostar 3 cycle neoadjuvant DE . All case receive mammography , contrast-enhanced ultrasound ( CEUS ) , magnetic resonance angiography ( MRA ) , positron emission tomography ( PET ) scan pre- post-neoadjuvant therapy , undergo surgical resection . The primary endpoint clinical/pathological response . The clinical response evaluate accord RECIST criterion . The parameter tumor metabolism blood supply , demonstrate PET , MRA CEUS , collect analyse . The secondary endpoint ( 1 ) number participant adverse event , ( 2 ) quality life score , ( 3 ) number adverse event report neoadjuvant therapy . In addition , role mammography , CEUS , MRA PET response evaluation , well angiogenic profile biological information involve tumor response investigate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histologically confirm invasive breast cancer ( core needle biopsy breast cancer diagnosis fine needle aspiration lymph node metastasis diagnosis ) Stage ⅡAⅢC Age 1870 ECOG performance status 02 No evidence distant metastasis No previous therapy Normal hematologic function leave ventricular ejection fraction great 50 percent No abnormality renal liver function Written inform consent With allergic constitution possible allergic reflection drug use study Any concurrent uncontrolled medical psychiatric disorder History severe heart disease , include congestive heart failure , unstable angina , uncontrolled arrhythmia , myocardial infarction , uncontrolled high blood pressure , heart valve disease . History bleed diathesis Being pregnant nursing</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>recombinant human endostatin ( endostar )</keyword>
	<keyword>docetaxel</keyword>
	<keyword>epirubicin</keyword>
</DOC>